YAP and TAZ activity is often upregulated in cancer cells, but their activity is typically silent in normal resting tissue, suggesting that systemic YAP/TAZ inhibition allows cancer treatment without causing significant side effects (30, 117) (Figure 5). Here, YAP1 is linked to cancer.